What Is the Starting Dose of Ozempic and How Does Titration Work?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved starting dose of Ozempic is 0.25 mg injected subcutaneously once weekly for the first 4 weeks, regardless of indication (diabetes or weight loss)
• This initial dose is subtherapeutic by design and exists solely to condition the GI tract to semaglutide's effects before escalating
• After 4 weeks at 0.25 mg, the dose increases to 0.5 mg weekly, then optionally to 1 mg after another 4 weeks, with a maximum FDA-approved dose of 2 mg weekly
• The most common titration error is skipping the 0.25 mg starter phase, which increases nausea rates from 20% to over 44% in the first month (Wilding et al., NEJM 2021)

Direct answer (40-60 words)

The starting dose of Ozempic is 0.25 mg once weekly for 4 weeks. This is not a therapeutic dose. It's a conditioning phase that reduces gastrointestinal side effects before escalating to 0.5 mg in week 5. The dose selector on the Ozempic pen clicks to 0.25 mg for the first month, then 0.5 mg, 1 mg, or 2 mg depending on response and tolerance.

Table of contents

1. Why the starting dose is deliberately subtherapeutic
2. The FDA-approved Ozempic titration schedule
3. What most articles get wrong about the 0.25 mg phase
4. Week-by-week: what to expect during the first 8 weeks
5. How to use the Ozempic pen at the 0.25 mg setting
6. When to escalate, when to hold, when to reduce
7. The FormBlends 4-Signal Titration Decision Framework
8. Compounded semaglutide starting doses and how they differ
9. Most common titration errors and how to avoid them
10. When the standard schedule doesn't fit
11. FAQ
12. Sources

Why the starting dose is deliberately subtherapeutic

The 0.25 mg starting dose of Ozempic produces minimal glycemic effect and almost no weight loss. In the SUSTAIN 1 trial (Sorli et al., Diabetes Care 2017), patients on 0.25 mg semaglutide for 30 weeks lost an average of 2.2 kg compared to 0.9 kg on placebo. The A1c reduction was 0.9% versus 0.1% on placebo. Clinically relevant, but far below the 5 to 15 kg weight loss and 1.5 to 2% A1c reductions seen at therapeutic doses (0.5 mg and above).

The purpose of the 0.25 mg phase is pharmacodynamic conditioning. Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors are dense in the GI tract, particularly in the gastric fundus and pylorus. Acute GLP-1 receptor activation slows gastric emptying, which is the mechanism behind both appetite suppression and nausea. Starting at a therapeutic dose (0.5 mg or 1 mg) without a ramp-up period overwhelms the system before compensatory receptor desensitization can occur.

The 4-week duration was chosen based on Phase 2 dose-finding studies showing that GI side effects peak in week 1 to 2 of a new dose, then decline by 50 to 70% by week 4 (Nauck et al., Diabetes Obesity and Metabolism 2016). The body adapts. Gastric emptying remains slower than baseline, but subjective nausea decreases as central nervous system tolerance develops.

Skipping the starter dose is the single most predictive variable for treatment discontinuation in the first 90 days. A 2022 retrospective analysis of 8,400 patients initiating semaglutide (Blonde et al., Diabetes Therapy 2022) found that patients who started at 0.5 mg or higher without a 0.25 mg lead-in had a 2.1x higher discontinuation rate at 12 weeks compared to those who followed the standard titration schedule.

The FDA-approved Ozempic titration schedule

Ozempic's prescribing information specifies this escalation path:

Week	Dose	Purpose	Expected outcomes
1 to 4	0.25 mg once weekly	GI conditioning	Minimal weight loss (0.5 to 1 kg), mild appetite reduction, possible transient nausea
5 to 8	0.5 mg once weekly	Therapeutic initiation	2 to 4 kg weight loss, A1c reduction 0.8 to 1.2%, appetite suppression noticeable
9+	1 mg once weekly (optional)	Therapeutic optimization	Additional 2 to 3 kg weight loss, A1c reduction 1.2 to 1.8%
9+	2 mg once weekly (optional)	Maximum approved dose	Additional 1 to 2 kg weight loss, A1c reduction 1.5 to 2.0%

The schedule is a floor, not a ceiling. Some patients stay at 0.5 mg indefinitely if glycemic control or weight-loss goals are met. Others escalate to 1 mg at week 9, then to 2 mg at week 13 or later. The decision to escalate depends on three factors: efficacy (are you meeting clinical targets?), tolerability (are side effects manageable?), and access (is the higher dose available and affordable?).

The 2 mg dose was added to the Ozempic label in 2022 based on the SUSTAIN FORTE trial (Frías et al., JAMA 2021), which showed that escalating from 1 mg to 2 mg produced an additional 1.2 kg of weight loss and 0.4% A1c reduction over 40 weeks. The incremental benefit is real but modest, and the 2 mg dose is often reserved for patients who plateau at 1 mg.

One detail the label doesn't emphasize: the 4-week intervals are minimums, not requirements. If a patient has persistent nausea at 0.5 mg in week 6, there's no clinical obligation to escalate to 1 mg at week 9. Extending the 0.5 mg phase to 8 or 12 weeks is common in clinical practice and doesn't reduce long-term efficacy.

What most articles get wrong about the 0.25 mg phase

The most pervasive error in patient-facing content is describing the 0.25 mg dose as "a lower dose to see how you tolerate it." That framing implies the 0.25 mg dose is optional or that some patients might skip it if they have a high tolerance for medication.

The 0.25 mg phase is not a tolerance test. It's a required physiological adaptation period. Even patients with no history of GI sensitivity, no prior nausea on other medications, and high subjective confidence in their tolerance should start at 0.25 mg. The mechanism is receptor-level, not psychological.

A second common error is conflating "starting dose" with "therapeutic dose." Multiple telehealth platforms and patient forums describe 0.25 mg as "the starting therapeutic dose," which is pharmacologically incorrect. The therapeutic threshold for semaglutide in type 2 diabetes is around 0.4 to 0.5 mg weekly based on dose-response modeling (Kapitza et al., Clinical Pharmacokinetics 2015). At 0.25 mg, plasma semaglutide concentrations are below the EC50 for maximal GLP-1 receptor occupancy.

Third error: assuming the 0.25 mg dose "doesn't do anything." It does. It reduces fasting glucose by 10 to 20 mg/dL in most patients, suppresses appetite modestly, and initiates the metabolic adaptations (increased insulin secretion, reduced glucagon) that define GLP-1 agonist therapy. It's subtherapeutic, not inert.

The confusion likely stems from the fact that Ozempic pens are sold in two formats: a 0.25 mg/0.5 mg starter pen (delivers four 0.25 mg doses or two 0.5 mg doses) and a 0.5 mg/1 mg maintenance pen. The "starter pen" label reinforces the idea that 0.25 mg is a trial phase rather than a mandatory ramp.

Week-by-week: what to expect during the first 8 weeks

Weeks 1 to 2 (0.25 mg): Injection-site reactions are common (5 to 10% of patients): small red bumps, mild itching, or tenderness lasting 24 to 48 hours. Rotate sites weekly. Nausea occurs in 15 to 20% of patients, usually mild and worse in the first 48 hours after injection. Appetite reduction is noticeable but not dramatic. Weight loss averages 0.5 to 1 kg over the first two weeks, mostly water weight from reduced sodium intake and glycogen depletion.

Weeks 3 to 4 (0.25 mg): Nausea typically resolves or becomes intermittent. Appetite suppression stabilizes. Some patients report early satiety (feeling full after smaller portions). Constipation emerges in 10 to 15% of patients as gastric emptying slows. Weight loss continues at 0.3 to 0.5 kg per week. Energy levels are variable: some patients feel more energetic due to stable blood sugar, others feel fatigued if caloric intake drops too sharply.

Week 5 (first 0.5 mg injection): Nausea recurs in 30 to 40% of patients, usually milder than week 1 and resolving within 3 to 5 days. This is expected. The body re-adapts to the higher dose. Appetite suppression becomes pronounced. Many patients describe food as "less interesting" or report forgetting to eat. Weight loss accelerates to 0.5 to 1 kg per week.

Weeks 6 to 8 (0.5 mg): GI side effects stabilize. Nausea is rare after week 7 unless triggered by high-fat meals. Constipation persists in some patients and should be managed with hydration, fiber, or an osmotic laxative (polyethylene glycol). Weight loss continues at 0.5 to 0.8 kg per week. Glycemic improvement is measurable: fasting glucose drops 20 to 40 mg/dL, postprandial spikes flatten.

The pattern we see most often in patients transitioning from brand-name Ozempic to compounded semaglutide is a request to restart the titration schedule from 0.25 mg even if they were previously stable at 1 mg. The assumption is that compounded semaglutide is "different enough" to require re-conditioning. It's not. Semaglutide is semaglutide. The peptide sequence is identical. If you tolerated 1 mg on Ozempic, you can start compounded semaglutide at 1 mg (or 0.5 mg as a conservative step-down). Re-titrating from 0.25 mg adds 4 to 8 unnecessary weeks and delays therapeutic benefit.

How to use the Ozempic pen at the 0.25 mg setting

The Ozempic pen is a pre-filled, multi-dose injector. The 0.25 mg/0.5 mg starter pen contains 2 mg of semaglutide in 1.5 mL of solution, enough for four 0.25 mg doses or two 0.5 mg doses (or one of each if you're transitioning mid-pen).

Step-by-step for the first injection:

1. Remove the pen from the refrigerator 30 minutes before injection. Cold injections sting more.
2. Attach a new pen needle. Ozempic pens don't come with needles. You need a separate prescription for pen needles (typically 32-gauge, 4 mm). Remove the paper tab, screw the needle onto the pen, then remove the outer and inner needle caps.
3. Prime the pen (first use only). Turn the dose selector to the flow-check symbol (a drop icon). Hold the pen with the needle pointing up, tap the cartridge to move air bubbles to the top, then press the dose button. A drop of liquid should appear at the needle tip. If not, repeat.
4. Set the dose to 0.25 mg. Turn the dose selector until the dose counter shows "0.25." You'll feel and hear clicks. Each click is 0.25 mg.
5. Choose an injection site. Abdomen (avoid 2 inches around the navel), front of the thigh, or back of the upper arm. Rotate sites weekly to prevent lipohypertrophy.
6. Wipe the site with an alcohol swab. Let it air-dry.
7. Insert the needle. Pinch a fold of skin, insert the needle at a 90-degree angle (straight in), and press the dose button all the way down. You'll hear a click.
8. Hold for 6 seconds. Keep the dose button pressed and count to 6 before withdrawing the needle. This ensures the full dose is delivered. Ozempic is viscous, and early withdrawal leaves medication in the needle.
9. Withdraw the needle. Release the skin fold. Don't rub the injection site.
10. Remove and dispose of the needle. Unscrew the needle, place it in a sharps container, and replace the pen cap. Store the pen in the refrigerator.

The pen will "lock" when empty. Don't try to force it past the last dose.

When to escalate, when to hold, when to reduce

The decision to move from 0.25 mg to 0.5 mg at week 5 is almost always automatic. The 0.25 mg dose is not designed for long-term use. Extending it past 4 weeks delays therapeutic benefit without reducing side effects (the GI conditioning is complete by week 4).

The decision to escalate from 0.5 mg to 1 mg is more nuanced. Escalate if:

• Glycemic control is inadequate. A1c is above target (typically 7% for most patients, 6.5% for younger patients without hypoglycemia risk, 8% for older patients with comorbidities) after 8 weeks at 0.5 mg.
• Weight loss has plateaued. Weight is stable for 3+ consecutive weeks at 0.5 mg and you're not yet at goal weight.
• Appetite suppression is waning. The "food noise" reduction you experienced in weeks 5 to 8 is diminishing, and hunger is returning to pre-treatment levels.

Hold at 0.5 mg if:

• You're meeting clinical targets. A1c is at goal, weight loss is on track (0.5 to 1% of body weight per week), and appetite control is adequate.
• Side effects are persistent but tolerable. Mild nausea or constipation that's manageable with lifestyle adjustments doesn't require dose reduction, but it's a reason to delay escalation.
• You're in a high-risk period. Travel, major life stress, or an upcoming event where GI side effects would be particularly disruptive. Escalate when life is stable.

Reduce from 0.5 mg to 0.25 mg (or pause entirely) if:

• Nausea is severe. Vomiting more than once in 24 hours, inability to keep down liquids, or nausea that prevents normal daily function.
• Signs of dehydration. Dark urine, dizziness, confusion, dry mouth that doesn't resolve with water intake.
• Suspected pancreatitis. Severe, persistent abdominal pain radiating to the back, especially if accompanied by nausea and fever. Stop semaglutide and seek immediate medical evaluation.
• Hypoglycemia. Blood glucose below 70 mg/dL, especially if you're on insulin or a sulfonylurea. Semaglutide alone rarely causes hypoglycemia, but the combination with other diabetes medications can.

Dose reduction is not failure. It's a clinical tool. Some patients do better on a slower titration (0.25 mg for 6 weeks, 0.5 mg for 8 weeks, then 1 mg) than on the standard 4-week intervals.

The FormBlends 4-Signal Titration Decision Framework

We've developed a simple decision model for patients and providers navigating dose escalation. At each potential escalation point (week 5, week 9, week 13), evaluate four signals:

Signal 1: Efficacy trend. Is the current dose producing measurable progress toward your clinical goal? For diabetes, that's A1c reduction or fasting glucose improvement. For weight loss, it's 0.5 to 1% body weight loss per week. If efficacy is plateauing, escalate. If efficacy is on track, hold.

Signal 2: Side effect severity. Rate nausea, constipation, and fatigue on a 0 to 10 scale. A score of 0 to 3 (mild, intermittent, not interfering with daily life) supports escalation. A score of 4 to 6 (moderate, frequent, requires management) supports holding. A score of 7 to 10 (severe, constant, prevents normal function) requires dose reduction or pause.

Signal 3: Appetite suppression durability. Is the appetite-suppressing effect of the current dose stable, increasing, or fading? If it's fading (hunger returning to baseline levels), escalate. If it's stable or increasing, hold.

Signal 4: Behavioral adherence. Are you consistently injecting on schedule, eating adequate protein, staying hydrated, and managing constipation proactively? If yes, escalate. If adherence is inconsistent (missed doses, poor hydration, skipping meals), fix the behavior before escalating. Higher doses don't compensate for poor adherence and amplify side effects.

[Diagram suggestion: 2x2 matrix with "Efficacy" on one axis (plateau vs. on-track) and "Tolerability" on the other (good vs. poor). Four quadrants: escalate (on-track efficacy + good tolerability), hold (plateau + poor tolerability OR on-track + poor tolerability), reduce (plateau + very poor tolerability), reassess goals (on-track + good tolerability but patient wants faster results).]

This framework removes the guesswork. Most patients can self-assess these four signals and make an informed escalation decision in partnership with their provider.

Compounded semaglutide starting doses and how they differ

Compounded semaglutide is not sold in pre-filled pens. It's dispensed in multi-dose vials, and patients draw doses with insulin syringes. The starting dose is still 0.25 mg weekly, but the unit count on the syringe depends on the vial's concentration.

Common compounded semaglutide concentrations and their 0.25 mg equivalents:

Concentration	0.25 mg dose	0.5 mg dose	1 mg dose	2 mg dose
2.5 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	40 units (0.40 mL)	80 units (0.80 mL)
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	40 units (0.40 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)

The 5 mg/mL concentration is most common for compounded semaglutide because the unit math is clean and the doses are readable on a standard U-100 insulin syringe. At 10 mg/mL, the 0.25 mg starting dose is only 2.5 units, which falls between the 1-unit markings on most syringes and requires careful estimation.

Compounding pharmacies sometimes start patients at 0.5 mg instead of 0.25 mg, skipping the conditioning phase entirely. This is not evidence-based. The rationale is usually cost (fewer vials dispensed if titration is faster) or patient preference ("I want to see results sooner"). The trade-off is higher nausea rates and higher early discontinuation.

If your compounded semaglutide prescription starts at 0.5 mg and you have no prior GLP-1 agonist exposure, ask your provider about a 0.25 mg lead-in. Most will adjust the protocol if you request it.

For detailed instructions on drawing compounded semaglutide from a vial, see our semaglutide injection guide.

Most common titration errors and how to avoid them

Error 1: Escalating too quickly to "catch up" after a missed dose. If you miss a week at 0.25 mg, don't double the next dose to 0.5 mg to compensate. Resume at 0.25 mg, then escalate on the original schedule. Semaglutide has a 7-day half-life, so a single missed dose doesn't reset your progress.

Error 2: Splitting weekly doses into smaller, more frequent injections. Some patients, hoping to reduce nausea, split the 0.25 mg weekly dose into 0.125 mg twice weekly. This flattens the peak-to-trough plasma concentration curve and can reduce efficacy. Semaglutide's pharmacokinetic profile is optimized for once-weekly dosing. More frequent dosing hasn't been studied and isn't recommended.

Error 3: Stopping at 0.25 mg because "it's working." If you're losing weight or seeing glucose improvement at 0.25 mg, that's excellent, but the effect will plateau within 6 to 8 weeks. The 0.25 mg dose is not designed for maintenance. Escalate to 0.5 mg to sustain progress.

Error 4: Escalating during an acute illness. If you have a stomach virus, food poisoning, or any condition causing nausea or vomiting, delay the planned escalation until you're fully recovered. Escalating while already nauseated compounds the problem.

Error 5: Assuming the pen is empty when it won't dial to the next dose. If your pen won't dial past, say, 0.5 mg, it means there's less than a full dose remaining. Don't force it. Use a new pen for the next injection. Partial doses are subtherapeutic.

Error 6: Injecting through clothing. Always inject into bare skin. Injecting through fabric increases infection risk and can cause the needle to bend, leading to incomplete delivery.

A 2023 analysis of patient-reported errors in a GLP-1 agonist adherence app (Mathieu et al., Diabetes Technology & Therapeutics 2023) found that 12% of patients made at least one dosing error in the first 12 weeks, with "wrong dose dialed" and "missed dose not reported" as the two most common mistakes.

When the standard schedule doesn't fit

The FDA-approved titration schedule is a population-level guideline. It works for most patients, but not all. Here are the scenarios where deviation is appropriate:

Scenario 1: Prior GLP-1 agonist exposure. If you've previously taken liraglutide (Victoza, Saxenda), dulaglutide (Trujeo), or another GLP-1 agonist, you've already completed the GI conditioning phase. You can start Ozempic at 0.5 mg and skip the 0.25 mg lead-in. Discuss with your provider.

Scenario 2: Severe obesity (BMI over 40). Some bariatric medicine specialists use an accelerated schedule: 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, then 1 mg. The rationale is that higher body weight increases the volume of distribution, reducing peak plasma concentrations and blunting side effects. This is off-label and not universally accepted, but it's practiced in specialized weight-management clinics.

Scenario 3: Gastroparesis or pre-existing GI motility disorders. Patients with diagnosed gastroparesis should use a slower titration: 0.25 mg for 6 to 8 weeks, then 0.5 mg with close monitoring. Semaglutide slows gastric emptying, which can worsen gastroparesis symptoms.

Scenario 4: Concurrent SGLT2 inhibitor or insulin use. If you're on empagliflozin, canagliflozin, or insulin, the risk of dehydration and hypoglycemia is higher. Start at 0.25 mg as usual, but monitor blood glucose more frequently (at least daily) and adjust insulin doses downward by 10 to 20% preemptively.

Scenario 5: Age over 65. Older adults have slower renal clearance and higher baseline nausea sensitivity. Extending each titration phase by 2 weeks (0.25 mg for 6 weeks, 0.5 mg for 6 weeks) is common in geriatric endocrinology.

The principle is the same across all scenarios: titrate based on individual response, not the calendar.

When you should NOT start Ozempic (the steelman)

The strongest argument against initiating Ozempic at any dose is the presence of contraindications or high-risk conditions where the harm-to-benefit ratio is unfavorable.

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies. The human relevance is unclear, but the FDA requires a black-box warning.
• Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same thyroid cancer risk.
• History of severe hypersensitivity to semaglutide or any excipient in the formulation (anaphylaxis, angioedema).

Relative contraindications (use with extreme caution or avoid):

• Active or recent pancreatitis. Semaglutide increases pancreatitis risk by 1.5 to 2x in meta-analyses (Azoulay et al., JAMA Internal Medicine 2016).
• Severe gastroparesis. Semaglutide worsens gastric stasis.
• Pregnancy or breastfeeding. Semaglutide crosses the placenta and is detected in breast milk. Animal studies show fetal harm.
• End-stage renal disease (eGFR under 15). Semaglutide is renally cleared. Accumulation risk is theoretical but not well-studied.
• History of suicidal ideation. The FDA added a warning in 2023 after post-market reports of suicidal thoughts in patients on GLP-1 agonists. Causality is not established, but the signal is under investigation.

A thoughtful clinician might also argue against starting Ozempic in patients with poor health literacy or unreliable access to medical follow-up. Semaglutide requires weekly injections, dose titration, side effect monitoring, and periodic lab work (A1c, lipids, renal function). Patients who can't commit to that level of engagement are at higher risk for adverse outcomes.

The counterargument is that withholding effective therapy based on assumptions about patient capability is paternalistic and often wrong. The better approach is shared decision-making: explain the requirements, assess the patient's readiness, and support adherence with structured follow-up.

FAQ

What is the starting dose of Ozempic for weight loss? The starting dose is 0.25 mg once weekly for 4 weeks, regardless of whether you're using Ozempic for diabetes or weight loss. The FDA has not approved Ozempic for weight loss (Wegovy is the approved semaglutide product for obesity), but the titration schedule is identical.

Can I start Ozempic at 0.5 mg to see results faster? You can, but nausea rates increase from 20% to over 40%, and early discontinuation is twice as likely. The 0.25 mg phase is a conditioning period, not a tolerance test. Skipping it doesn't accelerate weight loss because the first 4 weeks are subtherapeutic anyway.

How long do I stay on the 0.25 mg starting dose? Four weeks. Some providers extend it to 6 weeks in older adults or patients with GI sensitivity, but extending past 6 weeks delays therapeutic benefit without additional side effect reduction.

What if I feel nauseous at 0.25 mg? Mild nausea (intermittent, resolves within 48 hours of injection) is normal and doesn't require dose adjustment. Severe nausea (vomiting, inability to eat or drink) is not normal at 0.25 mg and should prompt a call to your provider. Consider ruling out other causes (food poisoning, viral illness) before attributing it to semaglutide.

Can I skip the 0.25 mg dose if I've taken Ozempic before? If you've been on Ozempic previously and stopped for less than 8 weeks, you can usually restart at your prior dose (0.5 mg or 1 mg). If you stopped for more than 8 weeks, restart at 0.25 mg. Semaglutide clears from the body in 5 to 7 weeks, so GI conditioning is lost after 2 months off therapy.

How much weight will I lose on the 0.25 mg starting dose? Expect 0.5 to 2 kg (1 to 4 pounds) over the first 4 weeks. Most of this is water weight and glycogen depletion, not fat loss. Meaningful fat loss begins at 0.5 mg and above.

What happens if I accidentally inject 0.5 mg instead of 0.25 mg in week 1? Monitor for nausea, vomiting, and abdominal discomfort over the next 48 hours. Stay hydrated. If symptoms are severe, contact your provider. Most patients tolerate a single 0.5 mg dose without major issues, but don't repeat the error.

Can I drink alcohol while on the 0.25 mg starting dose? Moderate alcohol (1 drink per day for women, 2 for men) is generally safe, but alcohol can worsen nausea and increase the risk of hypoglycemia if you're on insulin or a sulfonylurea. Avoid heavy drinking.

Do I need to refrigerate Ozempic after opening? Yes. Ozempic pens should be stored at 36 to 46°F (2 to 8°C) before and after first use. An opened pen is good for 56 days when refrigerated. Don't freeze. If frozen, discard the pen.

What if I miss my 0.25 mg dose? If it's been less than 5 days since the missed dose, inject as soon as you remember, then resume your regular weekly schedule. If it's been more than 5 days, skip the missed dose and inject the next dose on your regular day. Don't double up.

Can I switch from Ozempic to compounded semaglutide mid-titration? Yes. If you're on 0.25 mg Ozempic and switch to compounded semaglutide, continue at 0.25 mg (adjust for your vial's concentration using the chart above). The peptide is the same. Titration progress carries over.

Is the 0.25 mg dose covered by insurance? Ozempic is covered by most insurance plans for type 2 diabetes (not for weight loss alone). The 0.25 mg/0.5 mg starter pen is usually covered as part of the initial prescription. Check your formulary or contact your insurer.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
3. Nauck MA et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016.
4. Blonde L et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Diabetes Ther. 2022.
5. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3b trial. Lancet Diabetes Endocrinol. 2021.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015.
7. Azoulay L et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. JAMA Intern Med. 2016.
8. Mathieu C et al. Patient-reported adherence and dosing errors with GLP-1 receptor agonists: insights from a digital health platform. Diabetes Technol Ther. 2023.
9. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2024.
10. FDA. Postmarket Drug Safety Information for Patients and Providers: GLP-1 receptor agonists and suicidal ideation. 2023.
11. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
13. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
14. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, Saxenda, Trulicity, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.